Accessibility Menu
Novo Nordisk logo

Novo Nordisk(NYSE) NVO

Market Cap$155.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1981)+41,344%
5 Year-2%
1 Year-11%
1 Month-5%
$46.39
+1.49%
+0.68Today
Pre market$46.82+$0.43 (+0.93%)
Novo Nordisk last closing stock price
MetricPriceDate
Last closeUSD 46.482026-08-19
Novo Nordisk stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.47%USD 45.802026-08-12
1 month-5.11%USD 48.982026-07-20
3 month+6.05%USD 43.832026-05-21
Year to date-4.25%USD 48.542025-12-31
1 year-11.06%USD 52.262025-08-19
3 year-44.69%USD 84.032023-08-18
5 year-2.35%USD 47.602021-08-20
Since inception+41,344.06%USD 0.111981-07-09

Novo Nordisk Financials at a Glance

Market Cap

$155.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 329.43B

Net Income (TTM)

DKK 116.44B

EPS (TTM)

$4.09

P/E Ratio

11.35

Dividend

$1.80

Beta (Volatility)

0.68 (Low)

Price

$46.39

Volume

142,130.192

Open

$46.01

Previous Close

$46.48

Daily Range

$45.84 - $47.20

52-Week Range

$35.12 - $64.16

Estimated Earnings Date

Nov 4, 2026

NVO News

A couple looking at a computer screen..jpg

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now

David Jagielski, CPAAug 18, 2026
Novo Nordisk logo

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Prosper Junior BakinyAug 13, 2026
mqdefault (4)

Novo Nordisk Stock: Buy or Sell?

Parkev Tatevosian, CFAAug 11, 2026
Novo Nordisk logo

Why Is Everyone Talking About Novo Nordisk?

Prosper Junior BakinyAug 6, 2026
GettyImages-1262327331-1200x800-5b2df79.jpg

Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?

John BromelsJul 31, 2026
Novo Nordisk logo

3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold

Prosper Junior BakinyJul 29, 2026
Pills on money

How to Buy Novo Nordisk Stock (NVO): Step-by-Step & What to Expect

Matt DiLalloJul 29, 2026
NVO

Where Will Novo Nordisk Stock Be in 3 Years?

Alex CarchidiJul 28, 2026
Page 1

NVO: Motley Fool Moneyball Superscore

72

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novo Nordisk

Novo Nordisk A/S is a leading global pharmaceutical company focused on the research, development, manufacturing, and distribution of medical products. The company specializes in diabetes and obesity care, as well as rare diseases, with a strong presence in Europe, North America, and Asia.

Products and Services
  • Diabetes and obesity care therapies
  • Rare disease treatments, including hormone replacement
  • Smart digital solutions for diabetes management
Growth Outlook
  • Projected revenue growth driven by increasing diabetes prevalence
  • Expansion into emerging markets enhances market reach
  • Strategic partnerships support innovative drug development
Financial Highlights
  • Q2 2026 revenue of 78.49 billion DKK, reflecting strong demand
  • Net income of 20.99 billion DKK in Q2 2026, showcasing profitability
  • TTM net profit margin of 35.35%, indicating operational efficiency
Novo Nordisk A/S has established itself as a key player in the pharmaceutical industry, particularly in diabetes and obesity care. The company's commitment to innovation is evident through its extensive research and development efforts, which are supported by strategic partnerships. Recent financial performance highlights a robust revenue stream and strong profitability, positioning the company favorably for future growth. With a focus on expanding into emerging markets and addressing the rising global demand for diabetes treatments, Novo Nordisk A/S presents a compelling opportunity for potential investors.
AI Generated • Aug 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

68,794

CEO

Maziar Mike Doustdar

Website

www.novonordisk.com

Headquarters

Bagsvaerd, CR 2880, DK

NVO Financials

Key Financial Metrics (TTM)

Gross Margin

80.65%

Operating Margin

43.13%

Net Income Margin

35.35%

Return on Equity

59.09%

Return on Capital

39.28%

Return on Assets

19.57%

Earnings Yield

8.81%

Dividend Yield

3.87%

Payout Ratio

44.64%

Stock Overview

Market Cap

$155.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.35B

Volume

142.13K

Avg. Volume

12.40M

Financials (TTM)

Gross Profit

DKK 265.68B

Operating Income

DKK 142.10B

EBITDA

DKK 180.91B

Operating Cash Flow

DKK 133.01B

Capital Expenditure

-DKK 84.09B

Free Cash Flow

DKK 48.92B

Cash & ST Invst.

DKK 44.98B

Total Debt

DKK 140.13B

Novo Nordisk Performance Analysis

Novo Nordisk annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 24,998,461,07711.7%
20232023-12-31DKK 33,700,297,29934.8%
20242024-12-31DKK 42,115,001,36325.0%
20252025-12-31DKK 46,735,785,02911.0%
Novo Nordisk sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.4%
Q42025-12-315.6%
Q12026-03-3122.3%
Q22026-06-30-18.9%
Novo Nordisk annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK 1.734.7%
20232023-12-31DKK 2.7056.5%
20242024-12-31DKK 3.2821.5%
20252025-12-31DKK 3.486.1%
Novo Nordisk sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-24.5%
Q42025-12-3134.2%
Q12026-03-3180.6%
Q22026-06-30-56.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

DKK 78.49B

+2.1%

Gross Profit

DKK 61.39B

-4.1%

Gross Margin

78.21%

N/A

Market Cap

$155.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.26M

N/A

Employees

68,794

N/A

Net Income

DKK 20.99B

-20.8%

EBITDA

DKK 38.68B

-11.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

DKK 44.98B

+137.6%

Total Debt

DKK 140.13B

+41.2%

Accounts Receivable

DKK 108.51B

+26.4%

Inventory

DKK 51.35B

+12.5%

Long Term Debt

DKK 121.79B

+39.5%

Short Term Debt

DKK 18.33B

+53.2%

Return on Assets

19.57%

N/A

Return on Invested Capital

39.93%

N/A

Free Cash Flow

DKK 42.40B

+73.0%

Operating Cash Flow

DKK 55.20B

+35.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PFEPfizer Inc.
$28.24+3.63%
GILDGilead Sciences, Inc.
$147.60+2.90%
ABTAbbott Laboratories
$114.46+1.58%
SNYSanofi
$45.83+1.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBSWebster Financial
$77.57-0.01%
IBITiShares Bitcoin Trust
$38.78+0.06%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.05+0.06%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$120.74-0.06%

Questions About NVO

What is the current price of Novo Nordisk?

Novo Nordisk is trading at $46.48 per share.

What is the 52-week range for Novo Nordisk?

Over the past 52 weeks, Novo Nordisk has traded between $35.12 and $64.16.

How much debt does Novo Nordisk have?

As of the most recent reporting period, Novo Nordisk reported total debt of DKK 21.43B.

How much cash does Novo Nordisk have on hand?

Novo Nordisk reported DKK 6.80B in cash and cash equivalents in its most recent financial results.

What is Novo Nordisk’s dividend yield?

Novo Nordisk currently has a dividend yield of 3.87%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services